Consensus Catalyst Pharmaceuticals, Inc.

Stocks

CPRX

US14888U1016

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 13:51:23 2026-06-18 EDT			5-day change	1st Jan Change
31.40 ^USD	-0.02%		+0.06%	+34.49%

05-22	CVC, GBL launch EUR10.7 billion bid for Italian drugmaker Recordati	RE
05-11	Catalyst Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise	MT

Evolution of the Average Target: Catalyst Pharmaceuticals, Inc.

Evolution of the Target Price: Catalyst Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Catalyst Pharmaceuticals, Inc.

2dd7041fafbb00dbba46a3d87d4.mjXDFf5u53d55cqEzqrQKjJ4YIcOf8lkLw4iTmRTwK4.xV2GSqs3rDJIkPLC-Oa3cGVAB9NpNaILRUNHPFRqttSrfJJckiuINBPTrQ~ff8da1d36f66198a719a890cec3b87a6

Analysts' recommendations: Catalyst Pharmaceuticals, Inc.

05-07	Oppenheimer Downgrades Catalyst Pharmaceuticals to Market Perform From Outperform	MT
01-07	Biopharma Sector Enters 2026 With Clearer Outlook, Key Catalysts, BofA Says	MT
25-08-06	Catalyst Pharmaceuticals Q2 revenue, adjusted EPS beats expectations, reaffirms 2025 revenue guidance	RE
25-04-21	BofA Adjusts Price Target on Catalyst Pharmaceuticals to $34 From $33	MT
25-02-28	Oppenheimer Adjusts Price Target on Catalyst Pharmaceuticals to $32 From $31, Maintains Outperform Rating	MT
25-02-04	Baird Initiates Coverage on Catalyst Pharmaceuticals With Outperform Rating, $28 Price Target	MT
24-11-11	Truist Securities Adjusts Price Target on Catalyst Pharmaceuticals to $36 From $30, Maintains Buy Rating	MT
24-08-09	Truist Adjusts Price Target on Catalyst Pharmaceuticals to $30 From $25, Maintains Buy Rating	MT
24-05-10	HC Wainwright Adjusts Catalyst Pharmaceuticals' Price Target to $26 From $24, Keeps Buy Rating	MT
24-03-14	Citigroup Starts Coverage on Catalyst Pharmaceuticals With Buy Rating, $27 Price Target	MT
24-03-07	BofA Securities Initiates Catalyst Pharmaceuticals With Buy Rating, Price Target is $23	MT
24-03-01	Cantor Fitzgerald Raises Catalyst Pharmaceuticals' Price Target to $34 From $27, Maintains Overweight Rating	MT
23-12-21	Oppenheimer Initiates Coverage on Catalyst Pharmaceuticals With Outperform Rating, $30 Price Target	MT
23-06-20	Truist Securities Adjusts Catalyst Pharmaceuticals Price Target to $24 From $22, Maintains Buy Rating	MT
23-01-19	Truist Securities Adjusts Catalyst Pharmaceuticals' Price Target to $22 From $18, Keeps Buy Rating	MT
22-12-21	Truist Securities Adjusts Price Target on Catalyst Pharmaceuticals to $18 From $17, Maintains Buy Rating	MT
22-12-21	HC Wainwright Adjusts Catalyst Pharmaceuticals' Price Target to $24 From $18, Keeps Buy Rating	MT
22-12-20	Piper Sandler Adjusts Catalyst Pharmaceuticals Price Target to $20 From $18, Maintains Overweight Rating	MT
22-08-24	Analyst recommendations: Intuit, XPeng, Rio Tinto, Prologis, Charter Communications...
22-08-24	Roth Capital Downgrades Catalyst Pharmaceuticals to Neutral From Buy; Price Target is $15.50	MT
22-08-11	Truist Securities Adjusts Catalyst Pharmaceuticals Price Target to $17 From $12, Maintains Buy Rating	MT
22-08-11	Cantor Fitzgerald Raises Catalyst Pharmaceuticals' Price Target to $18 From $15, Maintains Overweight Rating	MT
22-08-11	HC Wainwright Raises Catalyst Pharmaceuticals' Price Target to $18 From $12, Keeps Buy Rating	MT
22-08-11	Piper Sandler Adjusts Price Target on Catalyst Pharmaceuticals to $16 From $9, Reiterates Overweight Rating	MT
22-02-08	HC Wainwright Adjusts Catalyst Pharmaceuticals' Price Target to $12 From $9, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CATALYST PHARMACEUTICALS, INC.					+0.85%
	REGENERON PHARMACEUTICALS, INC.					+37.07%
	UCB					+15.87%
	SAMSUNG BIOLOGICS CO.,LTD.					+53%
	CSL LIMITED					+28.24%
	BIOGEN INC.					+10.8%
	MODERNA, INC.					-29.94%
	INCYTE CORPORATION					+10.46%
	INNOVENT BIOLOGICS, INC.					+57.05%
	SWEDISH ORPHAN BIOVITRUM AB					+7.1%
	Average					+19.05%
	Weighted average by Cap.					+23.78%